China Meheco Group Co., Ltd. (SHA:600056)
8.88
+0.10 (1.14%)
Sep 30, 2026, 3:00 PM CST
China Meheco Group Revenue
China Meheco Group had revenue of 8.76B CNY in the quarter ending June 30, 2026, with 2.51% growth. This brings the company's revenue in the last twelve months to 35.24B, up 3.59% year-over-year. In the year 2025, China Meheco Group had annual revenue of 35.36B with 0.34% growth.
Revenue (ttm)
35.24B
Revenue Growth
+3.59%
P/S Ratio
0.38
Revenue / Employee
4.43M
Employees
7,949
Market Cap
13.28B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.36B | 118.21M | 0.34% |
| Dec 31, 2024 | 35.24B | -3.58B | -9.22% |
| Dec 31, 2023 | 38.82B | 1.23B | 3.28% |
| Dec 31, 2022 | 37.59B | 1.36B | 3.75% |
| Dec 31, 2021 | 36.23B | -3.08B | -7.83% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Pharmaceuticals Holding | 289.46B |
| Jointown Pharmaceutical Group | 167.56B |
| C.Q. Pharmaceutical Holding | 81.39B |
| Guangzhou Baiyunshan Pharmaceutical Holdings Company | 77.91B |
| China National Accord Medicines Corporation | 72.89B |
| China National Medicines Corporation | 53.56B |
| Guangxi LiuYao Group | 21.15B |
| Liaoning Cheng Da | 9.21B |